https://www.selleckchem.com/products/alc-0159.html
SURPAS can define the "high risk" surgical population that may benefit from risk-mitigating interventions. Osimertinib is the standard of care in the initial treatment for advanced epidermal growth factor receptor (EGFR) mutation-positive lung cancer. However, clinical data and reliable prognostic biomarkers are insufficient. We performed a retrospective multicentre cohort study for 538 EGFR mutation-positive patients, who received osimertinib as the initial treatment between August 2018 and December 2019. The main outcome was progress
Like
Comment
Share
